Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
A very rare aggressive blood cancer of dendritic-cell precursors that often shows up as bruise-like skin lesions. Two CD123-directed drugs are the first targeted therapies; transplant is still needed for cure.
BPDCN derives from plasmacytoid dendritic cell precursors, expresses CD4, CD56, CD123 (IL-3 receptor alpha), TCF4 and TCL1, and presents with skin lesions, marrow involvement and cytopenias, often evolving to a leukaemic phase. Historically it was treated with ALL- or AML-type chemotherapy with brief responses and a median survival around a year.
Tagraxofusp (CD123-directed IL-3–diphtheria toxin fusion) was the first BPDCN-specific drug (2018), with ~70% response in untreated patients and capillary leak syndrome as its signature toxicity. Pivekimab sunirine (CD123 ADC) was approved in 2026 (CADENZA). Venetoclax-based regimens and hyper-CVAD are alternatives, and allogeneic transplant in first remission is the only route to long-term survival. CNS prophylaxis is recommended because of frequent occult CNS involvement.
State of the art today
- Two CD123-directed approvals (tagraxofusp 2018, pivekimab 2026) give a rare disease dedicated therapies.
- Transplant in first remission remains essential for cure; response to CD123 agents makes more patients eligible.
- BCL2 dependence makes venetoclax a rational partner.
BPDCN is very rare (a few hundred cases per year in the US); median age ~65-70, male predominance; skin lesions in most.
Where the cases are
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Tagraxofusp (monitor albumin for capillary leak) or pivekimab sunirine (2026); alternatives hyper-CVAD or venetoclax-based regimens; CNS prophylaxis.
Allogeneic HSCT in first complete remission for eligible patients; autologous transplant in selected cases (Japanese data).
Alternative CD123 agent, venetoclax combinations, clinical trials; prognosis poor.
Subtypes & biomarkers
top- Skin-only presentation
- Leukaemic / marrow-involving disease
- Cases arising with or from CMML/MDS
- CD123, CD4, CD56, TCF4, TCL1 immunophenotype
- Absence of MPO, lysozyme, CD3
- MYC rearrangement (8q24)
- TET2, ASXL1, ZRSR2 mutations
- CSF examination
Target prevalence in this cancer
- 2008WHO names BPDCN
Reclassified from 'CD4+/CD56+ haematodermic neoplasm' as a distinct entity.
- 2018Tagraxofusp approved
First CD123-targeted therapy and first drug approved for BPDCN.
- 2019Tagraxofusp NEJM pivotal data (Pemmaraju)
- 2026Pivekimab sunirine approved
CD123 ADC (CADENZA), FDA May 2026.
Open problems
- No randomised trials; sequencing of CD123 agents unknown.
- Capillary leak syndrome with tagraxofusp.
- Relapse after transplant.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Expert centres
topCentres linked to this cancer in OnCo
- via Allogeneic stem cell transplantation
- HOVONRotterdam, NLvia Venetoclax
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, IN, USNCI comprehensivevia Allogeneic stem cell transplantation
- Juravinski Cancer Centre / Escarpment Cancer Research InstituteHamilton, ON, CAvia Allogeneic stem cell transplantation
- via Allogeneic stem cell transplantation
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer CenterBaltimore, MD, USNCI comprehensivevia Allogeneic stem cell transplantation
- Walter and Eliza Hall Institute of Medical ResearchMelbourne, AUvia Venetoclax
Questions to ask
topQuestions to ask your oncologist about Blastic plasmacytoid dendritic cell neoplasm
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example CD123, CD4, CD56, TCF4, TCL1 immunophenotype, Absence of MPO, lysozyme, CD3, MYC rearrangement, TET2, ASXL1, ZRSR2 mutations, CSF examination), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Skin-only presentation, Leukaemic / marrow-involving disease, Cases arising with or from CMML/MDS.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
First line
- For my situation (first line), which of the standard options do you recommend and why?Why: Guideline options include: Tagraxofusp (monitor albumin for capillary leak) or pivekimab sunirine (2026); alternatives hyper-CVAD or venetoclax-based regimens; CNS prophylaxis.
- Am I a candidate for Tagraxofusp, Pivekimab sunirine, Venetoclax, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Consolidation
- For my situation (consolidation), which of the standard options do you recommend and why?Why: Guideline options include: Allogeneic HSCT in first complete remission for eligible patients; autologous transplant in selected cases (Japanese data).
Relapsed
- For my situation (relapsed), which of the standard options do you recommend and why?Why: Guideline options include: Alternative CD123 agent, venetoclax combinations, clinical trials; prognosis poor.
- Am I a candidate for Venetoclax, Pivekimab sunirine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Pivekimab sunirine, Venetoclax, Allogeneic stem cell transplantation?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trials; sequencing of CD123 agents unknown”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Capillary leak syndrome with tagraxofusp”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
6targets
2drugs
3companies
3pathways
1terms
1Latest papers
topQuery for this cancer: (TITLE:"Blastic plasmacytoid dendritic cell neoplasm" OR ABSTRACT:"Blastic plasmacytoid dendritic cell neoplasm" OR TITLE:"BPDCN" OR ABSTRACT:"BPDCN") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Blastic plasmacytoid dendritic cell neoplasm (BPDCN), not a curated reading list.